Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita

Friday, March 6, 2020 1 min read

Key Takeaway: Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita

Full Press Release Details

Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita.